EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
Biogen and partner UCB presented additional Phase 3 data for dapirolizumab pegol at the EULAR 2026 Congress, showing sustained disease control with reduced steroid exposure in systemic lupus erythematosus patients. Post-hoc analyses from the PHOENYCS GO study indicated that patients on dapirolizumab pegol were more likely to maintain disease control while tapering glucocorticoids to ≤7.5 mg/day through Week 48 compared to placebo.
Key figures
- Drug Name
- dapirolizumab pegol
- Phase Of Trial
- Phase 3
- Study name
- PHOENYCS GO
- Duration weeks
- 48
- Glucocorticoid taper threshold mg
- 7.5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.